文献速递心境障碍

杏仁核反应性、抗抑郁药停药与抑郁复发

Amygdala Reactivity, Antidepressant Discontinuation, and Relapse.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

该纵向观察研究在瑞士苏黎世和德国柏林的大学机构纳入缓解期重性抑郁障碍(MDD)成人患者,随机分配至第二次功能磁共振成像(fMRI)前或后停用抗抑郁药,随访6个月监测复发。停药后杏仁核反应性升高与抑郁复发相关(β=18.9;95%CI 0.8-37.1;P=.04),且与更短复发时间相关(HR=1.05;95%CI 1.01-1.09;P=.01)。

要点

  • 停药后杏仁核反应性升高与抑郁复发相关(β=18.9;95%CI 0.8-37.1;P=.04)。
  • 杏仁核反应性变化与更短复发时间相关(HR=1.05;95%CI 1.01-1.09;P=.01)。
  • 杏仁核反应性变化可预测复发(留一交叉验证平衡准确率67%;95%后验预测区间53-80;P=.02)。

核心结论

  • 停药后杏仁核反应性升高与抗抑郁药停药后复发风险相关,可能是一种功能性神经影像标志物,可为抗抑郁药停药的临床决策提供信息。

研究设计与样本

  • Antidepressiva Absetzstudie(AIDA)研究为纵向观察性研究,纳入缓解期MDD且正在服用抗抑郁药的成人患者,进行2次任务态fMRI测量杏仁核反应性。
  • 患者被随机分配至第二次fMRI测量前或后停用抗抑郁药,随访6个月监测复发。
  • 研究在瑞士苏黎世和德国柏林的大学机构进行,招募时间为2015年6月至2018年1月。
  • 共招募123例患者,83例纳入分析;招募66例年龄、性别和教育程度匹配的健康对照,53例纳入分析。

主要发现

  • 缓解期MDD服药患者的杏仁核反应性初始与对照无差异(t125.136=0.33;P=.74)。
  • 停药后杏仁核反应性升高与抑郁复发相关(组别[12W等待 vs 1W2停药]、时间点[MA1首次扫描 vs MA2第二次扫描]与复发的三阶交互作用:β=18.9;95%CI 0.8-37.1;P=.04)。
  • 杏仁核反应性变化与更短复发时间相关(HR=1.05;95%CI 1.01-1.09;P=.01)。
  • 杏仁核反应性变化可预测复发(留一交叉验证平衡准确率67%;95%后验预测区间53-80;P=.02)。
  • MDD患者平均(SD)年龄35.42(11.41)岁,62例(75%)为女性;对照平均(SD)年龄33.57(10.70)岁,37例(70%)为女性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Antidepressant discontinuation substantially increases the risk of a depression relapse, but the neurobiological mechanisms through which this happens are not known. Amygdala reactivity to negative information is a marker of negative affective processes in depression that is reduced by antidepressant medication, but it is unknown whether amygdala reactivity is sensitive to antidepressant discontinuation or whether any change is related to the risk of relapse after antidepressant discontinuation. OBJECTIVE: To investigate whether amygdala reactivity to negative facial emotions changes with antidepressant discontinuation and is associated with subsequent relapse. DESIGN, SETTING, AND PARTICIPANTS: The Antidepressiva Absetzstudie (AIDA) study was a longitudinal, observational study in which adult patients with remitted major depressive disorder (MDD) and currently taking antidepressants underwent 2 task-based functional magnetic resonance imaging (fMRI) measurements of amygdala reactivity. Patients were randomized to discontinuing antidepressants either before or after the second fMRI measurement. Relapse was monitored over a 6-month follow-up period. Study recruitment took place from June 2015 to January 2018. Data were collected between July 1, 2015, and January 31, 2019, and statistical analyses were conducted between June 2021 and December 2023. The study took place in a university setting in Zurich, Switzerland, and Berlin, Germany. Of 123 recruited patients, 83 were included in analyses. Of 66 recruited healthy control individuals matched for age, sex, and education, 53 were included in analyses. EXPOSURE: Discontinuation of antidepressant medication. OUTCOMES: Task-based fMRI measurement of amygdala reactivity and MDD relapse within 6 months after discontinuation. RESULTS: Among patients with MDD, the mean (SD) age was 35.42 (11.41) years, and 62 (75%) were women. Among control individuals, the mean (SD) age was 33.57 (10.70) years, and 37 (70%) were women. Amygdala reactivity of patients with remitted MDD and taking medication did not initially differ from that of control individuals (t125.136 = 0.33; P = .74). An increase in amygdala reactivity after antidepressant discontinuation was associated with depression relapse (3-way interaction between group [12W (waited) vs 1W2 (discontinued)], time point [MA1 (first scan) vs MA2 (second scan)], and relapse: β, 18.9; 95% CI, 0.8-37.1; P = .04). Amygdala reactivity change was associated with shorter times to relapse (hazard ratio, 1.05; 95% CI, 1.01-1.09; P = .01) and predictive of relapse (leave-one-out cross-validation balanced accuracy, 67%; 95% posterior predictive interval, 53-80; P = .02). CONCLUSIONS AND RELEVANCE: An increase in amygdala reactivity was associated with risk of relapse after antidepressant discontinuation and may represent a functional neuroimaging marker that could inform clinical decisions around antidepressant discontinuation.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Erdmann T, Berwian IM, Stephan KE, et al. Amygdala Reactivity, Antidepressant Discontinuation, and Relapse. JAMA Psychiatry. 2024. PMID: 39259548. doi:10.1001/jamapsychiatry.2024.2136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。